Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab

JAMA Dermatol. 2024 Jun 1;160(6):678-681. doi: 10.1001/jamadermatol.2024.1075.
No abstract available

Plain language summary

This post hoc analysis of PIONEER I and II randomized clinical trials assesses whether receiving adalimumab is associated with decreased hematologic abnormalities and increased clinical improvement in patients with hidradenitis suppurativa.

MeSH terms

  • Adalimumab* / administration & dosage
  • Adalimumab* / adverse effects
  • Adalimumab* / therapeutic use
  • Adult
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / therapeutic use
  • Female
  • Hematologic Diseases
  • Hidradenitis Suppurativa* / drug therapy
  • Humans
  • Male
  • Middle Aged

Substances

  • Adalimumab
  • Anti-Inflammatory Agents